PMV Pharmaceuticals
PMVP
99 hedge funds and large institutions have $72.7M invested in PMV Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 34 increasing their positions, 27 reducing their positions, and 15 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 27
1% more funds holding
Funds holding: 98 → 99 (+1)
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8.52% less ownership
Funds ownership: 91.61% → 83.09% (-8.5%)
50% less capital invested
Capital invested by funds: $145M → $72.7M (-$72.6M)
71% less call options, than puts
Call options by funds: $6K | Put options by funds: $21K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.45M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$2.44M |
| 3 |
Millennium Management
New York
|
+$1.22M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$905K |
| 5 |
D.E. Shaw & Co
New York
|
+$882K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$7.12M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$5.55M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$2.58M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$2.13M |
| 5 |
Vontobel Holding
Zurich,
Switzerland
|
-$2.13M |
PMVP Hedge Fund Activity: Q1 2024 in Review
99 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q1 2024, worth a combined $72.7M — down 50% from $145M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new PMVP positions and 15 closed out — a net gain of 1 holder — while 34 added to existing stakes and 27 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $2.45M. The largest seller was JP Morgan Chase, cutting an estimated $7.12M.
- 99 institutional investors held PMV Pharmaceuticals (PMVP) as of Q1 2024, up from 98 in Q4 2023.
- Funds reported $72.7M of PMV Pharmaceuticals stock for Q1 2024, down 50% quarter-over-quarter.
- 16 funds opened new PMV Pharmaceuticals positions in Q1 2024 and 15 closed out, a net change of +1 holder.
- The largest PMV Pharmaceuticals buyer in Q1 2024 was Acadian Asset Management, an estimated $2.45M added.
- The largest PMV Pharmaceuticals seller in Q1 2024 was JP Morgan Chase, an estimated $7.12M sold.
Based on aggregated 13F filings for Q1 2024.